Curis announced it has dosed the first five patients in its TakeAim CLL study testing emavusertib combined with the BTK inhibitor zanubrutinib for Chronic Lymphocytic Leukemia (CLL). This combination aims to improve treatment by dual inhibition of disease pathways, potentially leading to deeper remission and fixed-duration therapy. Initial data from 5-10 patients is expected by December 2026. The study addresses the limitations of current BTK inhibitor therapies, which often result in partial responses and residual disease.
Guangzhou's Nansha District is rapidly advancing as a global cross-border trade hub with its state-of-the-art automated container terminal and integrated multimodal transport system. In 2025, Nansha Port handled over 22.6 million TEUs and operates 18...
Nord Precious Metals Mining Inc., focused on high-grade silver mining in Northern Ontario, announced that CEO Frank J. Basa will present live at the OTCQB Virtual Investor Conference on August 5, 2026. The event allows investors to engage directly wi...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, effective August 6, 2026. Distribution rates vary widely across ETFs, reflecting different investment strategies and associated risks, including semiconductor, AI, crypto, metals, an...
The global military drone market is expected to grow from $16.5 billion in 2025 to $42.8 billion by 2035, at a CAGR of 10%. Growth is fueled by AI-powered autonomous systems, defense modernization, and rising demand for surveillance, electronic warfa...
Man Group PLC has disclosed a 1.66% interest in Senior Plc's ordinary shares, totaling 6,962,764 shares, held through cash-settled derivatives as of August 3, 2026. The stake was increased by 104,804 shares via an equity swap transaction priced at ap...
